However, a randomized controlled trial comparing placebo to monoclonal antibodies to VEGF in (mostly male) patients with metastatic clear-cell renal carcinoma resulted in a significant increase in the occurrence of hypertension and proteinuria in the treatment group24. This evidence concerns the gene VEGFA and hypertensive disorder.